RxDoctor Payments DataLook up a doctor →

Billy Hour, MD

Hospitalist · Mission Hills, CANPI 1790097004

Payments from drug & device makers

$1,926,262in general payments, 2019–2025

Across 710 payments — averaging $2713.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim International GmbH$614K
  • AstraZeneca$315K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$184K
  • Astrazeneca UK Limited$176K
  • GSK$137K
  • CSL Behring$121K
  • plus $379K from 26 others

What the payments were for

  • Speaking & faculty fees$2006%
  • Food & beverage$2,92488%
  • Education$1976%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,926,262 in reported general payments places this provider in the 95th percentile of 2,469 hospitalist providers in California.

See all hospitalist providers in California

Medicare billing

Part B allowed, 2024
$726,453
Medicare patients
755
Services billed
4,559

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpogenEpoetin Alfa19$17,596
LokelmaSodium Zirconium Cyclosilicate33$16,577
JardianceEmpagliflozin22$15,647
RetacritEpoetin Alfa-Epbx23$14,958
VeltassaPatiromer Calcium Sorbitex12$14,229
FarxigaDapagliflozin Propanediol16$11,812
Sevelamer Carbonate15$1,894
Calcitriol72$1,192
Bumetanide28$966
Calcium Acetate13$717
Hydralazine Hcl46$583
Spironolactone39$425
Allopurinol50$367
Cefdinir17$345
Minoxidil15$334

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma, Farxiga$315,032$28,38849 claims
AmgenEpogen$737$17,59619 claims
Boehringer IngelheimJardiance$18,679$15,64722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,469 hospitalist providers in California.

Other hospitalist in Mission Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →